Regulatory News:
Under the liquidity contract covering ABIONYX Pharma shares (FR0012616852 ABNX FP) entrusted to TP ICAP (Europe), the following assets were included in the liquidity account on December 31, 2025:
- Number of shares: 63,024
- Cash balance: 250,951.67
During the 2nd half of 2025, a total of
PURCHASE | 437,203 shares | 1,389,323.53 | 369 transactions |
SALE | 536,477 shares | 1,560,333.66 | 502 transactions |
As a reminder, at the half-yearly balance sheet dated June 30, 2025, the following assets were included in the liquidity account:
- Number of shares: 162,298 shares
- Cash balance: 86,279.52
When the liquidity contract was set up, the following resources were made available:
- Number of shares: 131,000 shares
- Cash balance: 40,801.20
ANNEX H2 2025
Purchases | Sales | |||||
ABNX FP | Number of transactions | Number of shares | Capital in EUR | Number of transactions | Number of shares | Capital in EUR |
Total | 369 | 437 203 | 1 389 323,53 | 502 | 536 477 | 1 560 333,66 |
20250701 | 1 | 1 | 1,19 | 3 | 2 902 | 3 492,92 |
20250702 | 1 | 1 | 1,21 | 2 | 224 | 271,49 |
20250703 | 2 | 2 271 | 2 707,06 | 2 | 2 | 2,44 |
20250704 | 1 | 1 | 1,21 | 1 | 1 | 1,21 |
20250707 | 1 | 1 | 1,21 | 1 | 1 | 1,21 |
20250708 | 1 | 1 | 1,21 | 1 | 1 | 1,21 |
20250709 | 1 | 1 | 1,19 | 1 | 1 | 1,19 |
20250710 | 1 | 1 | 1,21 | 1 | 1 | 1,21 |
20250711 | 1 | 1 | 1,21 | 2 | 1 781 | 2 172,81 |
20250714 | 1 | 1 | 1,22 | 2 | 32 | 39,17 |
20250715 | 1 | 1 | 1,23 | 1 | 1 | 1,23 |
20250716 | 1 | 1 | 1,23 | 1 | 1 | 1,23 |
20250717 | 1 | 1 | 1,23 | 1 | 1 | 1,23 |
20250718 | 1 | 1 | 1,23 | 2 | 2 211 | 2 746,05 |
20250721 | 1 | 1 | 1,26 | 2 | 153 | 193,08 |
20250722 | 1 | 1 | 1,25 | 1 | 1 | 1,25 |
20250723 | 1 | 1 | 1,26 | 5 | 8 691 | 11 045,44 |
20250724 | 1 | 1 | 1,30 | 5 | 12 291 | 16 286,42 |
20250725 | 3 | 3 681 | 4 900,69 | 4 | 7 551 | 10 418,87 |
20250728 | 1 | 1 | 1,39 | 11 | 30 861 | 44 685,19 |
20250729 | 3 | 4 551 | 6 939,43 | 11 | 23 541 | 38 883,67 |
20250730 | 7 | 16 231 | 28 984,31 | 1 | 1 | 1,85 |
20250731 | 11 | 26 661 | 43 396,07 | 1 | 1 | 1,75 |
20250801 | 5 | 8 061 | 12 270,79 | 5 | 8 409 | 13 719,53 |
20250804 | 1 | 1 | 1,63 | 9 | 22 381 | 37 265,25 |
20250805 | 3 | 3 082 | 5 176,63 | 5 | 8 621 | 15 063,56 |
20250806 | 1 | 1 | 1,73 | 4 | 3 162 | 5 499,94 |
20250807 | 6 | 13 921 | 22 958,52 | 1 | 1 | 1,74 |
20250808 | 6 | 11 283 | 17 654,04 | 1 | 1 | 1,61 |
20250811 | 1 | 1 | 1,60 | 6 | 16 139 | 26 625,15 |
20250812 | 1 | 1 | 1,67 | 1 | 1 | 1,67 |
20250813 | 1 | 1 | 1,82 | 5 | 8 561 | 15 592,26 |
20250814 | 2 | 3 041 | 5 552,91 | 6 | 9 801 | 18 728,69 |
20250815 | 3 | 4 441 | 8 081,58 | 3 | 2 471 | 4 694,90 |
20250818 | 1 | 1 | 1,85 | 5 | 7 381 | 13 761,45 |
20250819 | 1 | 1 | 1,90 | 5 | 6 761 | 13 001,38 |
20250820 | 1 | 1 | 1,92 | 2 | 1 041 | 1 994,56 |
20250821 | 1 | 1 | 1,91 | 4 | 4 111 | 7 922,95 |
20250822 | 1 | 1 | 1,92 | 11 | 16 261 | 33 277,95 |
20250825 | 1 | 1 | 2,15 | 11 | 12 341 | 28 080,35 |
20250826 | 9 | 29 511 | 61 139,20 | 4 | 2 261 | 5 134,54 |
20250827 | 1 | 1 | 2,06 | 11 | 15 911 | 35 190,61 |
20250828 | 1 | 1 | 3,00 | 11 | 12 281 | 36 843,00 |
20250829 | 3 | 4 451 | 12 561,07 | 11 | 9 471 | 29 076,87 |
20250901 | 1 | 1 | 3,58 | 11 | 8 281 | 30 366,58 |
20250902 | 11 | 21 591 | 88 354,20 | 5 | 2 251 | 10 356,40 |
20250903 | 7 | 11 071 | 39 819,29 | 3 | 1 321 | 5 059,59 |
20250904 | 1 | 1 | 3,67 | 9 | 9 931 | 37 813,67 |
20250905 | 6 | 9 721 | 35 058,97 | 2 | 146 | 554,77 |
20250908 | 10 | 17 481 | 58 490,32 | 1 | 1 | 3,67 |
20250909 | 2 | 1 071 | 3 288,01 | 3 | 4 301 | 15 058,31 |
20250910 | 5 | 4 381 | 15 945,72 | 2 | 1 111 | 4 210,62 |
20250911 | 1 | 1 | 3,69 | 10 | 16 481 | 63 688,84 |
20250912 | 2 | 1 741 | 6 624,56 | 5 | 5 471 | 21 652,16 |
20250915 | 1 | 1 | 4,05 | 7 | 7 691 | 31 674,55 |
20250916 | 2 | 1 951 | 7 999,10 | 1 | 1 | 4,10 |
20250917 | 3 | 2 701 | 10 539,33 | 1 | 1 | 3,93 |
20250918 | 5 | 7 061 | 26 397,84 | 4 | 1 418 | 5 548,50 |
20250919 | 1 | 1 | 3,98 | 4 | 3 861 | 15 370,43 |
20250922 | 4 | 4 521 | 16 592,07 | 4 | 3 551 | 13 974,17 |
20250923 | 1 | 1 | 3,90 | 2 | 741 | 2 897,30 |
20250924 | 2 | 2 151 | 8 238,42 | 5 | 4 321 | 17 201,42 |
20250925 | 3 | 2 981 | 11 542,61 | 2 | 701 | 2 775,91 |
20250926 | 8 | 11 691 | 42 489,70 | 1 | 1 | 3,80 |
20250929 | 1 | 1 | 3,65 | 1 | 1 | 3,65 |
20250930 | 6 | 8 666 | 27 625,95 | 3 | 1 801 | 6 087,45 |
20251001 | 1 | 1 | 3,30 | 5 | 5 201 | 17 679,60 |
20251002 | 4 | 4 031 | 14 056,97 | 1 | 1 | 3,57 |
20251003 | 1 | 1 | 3,50 | 2 | 961 | 3 363,50 |
20251006 | 4 | 3 981 | 13 425,80 | 3 | 1 941 | 6 793,50 |
20251007 | 3 | 2 571 | 8 573,54 | 1 | 1 | 3,34 |
20251008 | 1 | 1 | 3,36 | 5 | 6 041 | 20 796,66 |
20251009 | 3 | 2 661 | 9 086,46 | 3 | 1 901 | 6 672,66 |
20251010 | 4 | 3 981 | 13 624,80 | 1 | 1 | 3,50 |
20251013 | 1 | 1 | 3,31 | 6 | 7 491 | 25 790,01 |
20251014 | 4 | 4 201 | 14 399,15 | 1 | 1 | 3,45 |
20251015 | 1 | 1 | 3,36 | 7 | 9 231 | 32 617,96 |
20251016 | 2 | 694 | 2 415,21 | 3 | 1 681 | 6 014,02 |
20251017 | 3 | 2 941 | 10 387,78 | 1 | 1 | 3,58 |
20251020 | 5 | 6 851 | 23 172,65 | 5 | 5 071 | 18 272,75 |
20251021 | 6 | 9 251 | 29 989,79 | 1 | 1 | 3,39 |
20251022 | 1 | 1 | 3,60 | 11 | 16 811 | 60 519,60 |
20251023 | 4 | 4 571 | 16 671,75 | 5 | 4 621 | 17 702,95 |
20251024 | 1 | 1 | 3,80 | 10 | 11 221 | 44 748,50 |
20251027 | 4 | 3 720 | 14 789,73 | 10 | 8 961 | 38 919,58 |
20251028 | 1 | 1 | 4,55 | 11 | 9 141 | 43 405,35 |
20251029 | 9 | 17 141 | 80 006,34 | 5 | 2 491 | 12 793,24 |
20251030 | 7 | 10 551 | 45 404,28 | 1 | 1 | 4,48 |
20251031 | 5 | 6 161 | 25 646,05 | 5 | 4 551 | 20 164,05 |
20251103 | 3 | 2 641 | 10 780,86 | 5 | 4 691 | 20 122,46 |
20251104 | 3 | 2 791 | 11 169,73 | 6 | 5 701 | 24 018,23 |
20251105 | 6 | 8 891 | 35 906,45 | 1 | 1 | 4,15 |
20251106 | 1 | 1 | 3,93 | 10 | 12 201 | 50 259,43 |
20251107 | 3 | 4 101 | 17 236,46 | 5 | 3 771 | 16 503,76 |
20251110 | 4 | 4 481 | 18 568,60 | 2 | 681 | 2 914,60 |
20251111 | 1 | 1 | 4,18 | 4 | 2 941 | 12 445,78 |
20251112 | 7 | 10 501 | 42 742,65 | 5 | 4 111 | 18 133,25 |
20251113 | 3 | 2 821 | 11 148,77 | 3 | 1 581 | 6 434,67 |
20251114 | 2 | 291 | 1 155,34 | 4 | 1 631 | 6 663,64 |
20251117 | 1 | 1 | 4,28 | 5 | 4 631 | 19 850,73 |
20251118 | 3 | 2 871 | 11 949,27 | 1 | 1 | 4,17 |
20251119 | 1 | 1 | 4,22 | 3 | 1 541 | 6 572,62 |
20251120 | 3 | 2 821 | 11 769,34 | 3 | 1 481 | 6 361,14 |
20251121 | 1 | 1 | 4,35 | 9 | 9 551 | 42 161,65 |
20251124 | 4 | 4 901 | 20 063,60 | 1 | 1 | 4,20 |
20251125 | 1 | 1 | 4,18 | 5 | 4 061 | 17 465,18 |
20251126 | 5 | 6 881 | 29 098,30 | 1 | 1 | 4,30 |
20251127 | 3 | 2 224 | 9 072,46 | 1 | 1 | 4,08 |
20251128 | 2 | 2 111 | 8 528,48 | 1 | 1 | 4,08 |
20251201 | 4 | 4 241 | 17 022,46 | 1 | 1 | 4,06 |
20251202 | 4 | 4 071 | 15 973,93 | 1 | 1 | 4,03 |
20251203 | 5 | 6 181 | 23 005,50 | 1 | 1 | 3,80 |
20251204 | 1 | 1 | 3,79 | 5 | 5 881 | 22 765,19 |
20251205 | 1 | 1 | 3,91 | 3 | 1 851 | 7 265,61 |
20251208 | 1 | 1 | 3,90 | 1 | 1 | 3,90 |
20251209 | 3 | 2 671 | 10 208,65 | 2 | 891 | 3 483,75 |
20251210 | 4 | 3 951 | 14 989,23 | 1 | 1 | 3,83 |
20251211 | 4 | 3 851 | 14 083,72 | 1 | 1 | 3,72 |
20251212 | 4 | 3 721 | 13 236,49 | 2 | 1 011 | 3 710,29 |
20251215 | 1 | 1 | 3,53 | 2 | 1 051 | 3 731,03 |
20251216 | 4 | 3 721 | 12 713,02 | 1 | 1 | 3,42 |
20251217 | 9 | 12 721 | 39 905,26 | 1 | 1 | 3,16 |
20251218 | 1 | 1 | 3,20 | 6 | 9 481 | 31 218,90 |
20251219 | 1 | 1 | 3,41 | 6 | 8 501 | 29 709,51 |
20251222 | 5 | 5 991 | 20 522,54 | 1 | 1 | 3,54 |
20251223 | 1 | 1 | 3,40 | 4 | 4 381 | 15 331,30 |
20251224 | 1 | 1 | 3,49 | 3 | 2 111 | 7 462,79 |
20251225 | 0 | 0 | 0,00 | 0 | 0 | 0,00 |
20251226 | 0 | 0 | 0,00 | 0 | 0 | 0,00 |
20251229 | 3 | 2 591 | 8 925,20 | 2 | 1 011 | 3 568,80 |
20251230 | 2 | 1 831 | 6 408,52 | 5 | 6 101 | 22 274,12 |
20251231 | 1 | 1 | 3,67 | 6 | 7 291 | 27 527,77 |
About ABIONYX Pharma
ABIONYX Pharma is a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through breakthrough biotherapies that address life-threatening conditions with no effective treatments. Leveraging its proprietary apoA-I-based technology platform, ABIONYX Pharma develops innovative biologics and HDL-derived vectors that target the immune and inflammatory dysregulation underlying sepsis and other severe diseases. With a strong scientific foundation and a growing network of global clinical partners, ABIONYX Pharma aims to redefine the standard of care in sepsis and to bring critical care solutions to patients worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260107590484/en/
Contacts:
ABIONYX Pharma
infos@abionyx.com
